 Michael McDermott
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 5 | 2020 | 28 | 1.730 |
Why?
| | Hypothyroidism | 5 | 2020 | 71 | 1.640 |
Why?
| | Thyroid Neoplasms | 3 | 2020 | 308 | 0.840 |
Why?
| | Graves Disease | 2 | 2020 | 35 | 0.760 |
Why?
| | Osteoporosis | 5 | 2009 | 233 | 0.740 |
Why?
| | Triiodothyronine | 3 | 2020 | 44 | 0.730 |
Why?
| | Iodine Radioisotopes | 5 | 2020 | 142 | 0.670 |
Why?
| | Thyroxine | 3 | 2020 | 62 | 0.650 |
Why?
| | Bone Density Conservation Agents | 2 | 2009 | 74 | 0.580 |
Why?
| | Thyroid Diseases | 4 | 2005 | 35 | 0.570 |
Why?
| | Thyrotropin | 5 | 2020 | 109 | 0.570 |
Why?
| | Thyrotoxicosis | 2 | 2020 | 10 | 0.540 |
Why?
| | Vitamins | 2 | 2008 | 171 | 0.530 |
Why?
| | Antithyroid Agents | 4 | 2020 | 13 | 0.510 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1206 | 0.510 |
Why?
| | Vitamin D | 3 | 2008 | 384 | 0.500 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 45 | 0.390 |
Why?
| | Vitamin D Deficiency | 3 | 2009 | 179 | 0.370 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1435 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2016 | 2421 | 0.340 |
Why?
| | Self Administration | 2 | 2025 | 126 | 0.300 |
Why?
| | Premenopause | 1 | 2009 | 126 | 0.300 |
Why?
| | Patient Education as Topic | 2 | 2015 | 734 | 0.300 |
Why?
| | Thyroidectomy | 2 | 2020 | 88 | 0.260 |
Why?
| | Thyroid Hormones | 2 | 2020 | 54 | 0.260 |
Why?
| | Endocrinology | 2 | 2004 | 73 | 0.260 |
Why?
| | Pharmacists | 1 | 2008 | 259 | 0.250 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 91 | 0.240 |
Why?
| | Bone Density | 4 | 2009 | 470 | 0.230 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.230 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2013 | 0.230 |
Why?
| | Hospitalization | 2 | 2020 | 2080 | 0.220 |
Why?
| | Reproductive Medicine | 1 | 2004 | 14 | 0.220 |
Why?
| | Humans | 31 | 2025 | 128896 | 0.220 |
Why?
| | Professional Practice | 1 | 2003 | 65 | 0.210 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2002 | 5 | 0.210 |
Why?
| | Hydrocortisone | 1 | 2025 | 300 | 0.200 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1020 | 0.200 |
Why?
| | Blood Glucose | 2 | 2016 | 2086 | 0.200 |
Why?
| | Whole-Body Counting | 1 | 2002 | 6 | 0.200 |
Why?
| | Thyroglobulin | 1 | 2002 | 26 | 0.190 |
Why?
| | Point Mutation | 1 | 2002 | 226 | 0.190 |
Why?
| | Hip Fractures | 1 | 2003 | 82 | 0.190 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 991 | 0.190 |
Why?
| | Insulin | 2 | 2016 | 2311 | 0.190 |
Why?
| | Thyroid Gland | 1 | 2002 | 94 | 0.190 |
Why?
| | Methimazole | 1 | 2020 | 6 | 0.180 |
Why?
| | Myxedema | 1 | 2020 | 1 | 0.180 |
Why?
| | Glucocorticoids | 1 | 2025 | 570 | 0.170 |
Why?
| | Absorptiometry, Photon | 3 | 2009 | 249 | 0.170 |
Why?
| | Treatment Failure | 1 | 2020 | 345 | 0.160 |
Why?
| | Diet | 1 | 2007 | 1205 | 0.160 |
Why?
| | Mass Screening | 3 | 2020 | 1121 | 0.160 |
Why?
| | Physical Examination | 1 | 2020 | 237 | 0.160 |
Why?
| | Risk Factors | 5 | 2020 | 9792 | 0.150 |
Why?
| | Female | 17 | 2025 | 68162 | 0.150 |
Why?
| | Triiodothyronine, Reverse | 1 | 2018 | 2 | 0.150 |
Why?
| | Reference Values | 1 | 2020 | 791 | 0.150 |
Why?
| | Thyroid Function Tests | 1 | 2018 | 14 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1523 | 0.150 |
Why?
| | Practice Patterns, Physicians' | 2 | 2006 | 1281 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 320 | 0.150 |
Why?
| | Hypoglycemia | 2 | 2016 | 427 | 0.140 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 100 | 0.140 |
Why?
| | Insulin Antibodies | 1 | 2016 | 104 | 0.120 |
Why?
| | Biomarkers | 2 | 2020 | 3874 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2020 | 487 | 0.120 |
Why?
| | Rituximab | 1 | 2016 | 161 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2020 | 727 | 0.120 |
Why?
| | Aged | 10 | 2025 | 22035 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 952 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2016 | 227 | 0.110 |
Why?
| | Ambulatory Care | 2 | 2008 | 509 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2015 | 227 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3334 | 0.100 |
Why?
| | Pregnancy | 3 | 2020 | 6247 | 0.100 |
Why?
| | Thyroid Crisis | 1 | 2012 | 7 | 0.100 |
Why?
| | Sex Factors | 2 | 2012 | 1947 | 0.100 |
Why?
| | Age Factors | 2 | 2012 | 3133 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 419 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2008 | 7050 | 0.100 |
Why?
| | Postpartum Thyroiditis | 1 | 2011 | 1 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 255 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 539 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 370 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2020 | 14546 | 0.090 |
Why?
| | Male | 11 | 2025 | 63146 | 0.080 |
Why?
| | Risk | 1 | 2012 | 866 | 0.080 |
Why?
| | Liver Diseases | 1 | 2012 | 284 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 45 | 0.080 |
Why?
| | Colorado | 4 | 2009 | 4443 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 366 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 98 | 0.070 |
Why?
| | Obesity | 2 | 2015 | 2844 | 0.070 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 15 | 0.070 |
Why?
| | Patient Care | 1 | 2008 | 109 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 58 | 0.070 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 83 | 0.070 |
Why?
| | Pilot Projects | 2 | 2009 | 1545 | 0.070 |
Why?
| | Professional Role | 1 | 2008 | 157 | 0.070 |
Why?
| | Nutrition Policy | 1 | 2007 | 56 | 0.070 |
Why?
| | Middle Aged | 7 | 2025 | 30977 | 0.070 |
Why?
| | Insulin Lispro | 1 | 2006 | 36 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 92 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 459 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 69 | 0.070 |
Why?
| | Serum Albumin | 1 | 2007 | 145 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1264 | 0.060 |
Why?
| | Women's Health | 1 | 2009 | 361 | 0.060 |
Why?
| | Body Composition | 1 | 2009 | 654 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5355 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 485 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2009 | 610 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 563 | 0.060 |
Why?
| | Outpatients | 1 | 2007 | 366 | 0.050 |
Why?
| | Fractures, Bone | 1 | 2009 | 416 | 0.050 |
Why?
| | Densitometry | 1 | 2003 | 32 | 0.050 |
Why?
| | Thyroid Nodule | 1 | 2003 | 51 | 0.050 |
Why?
| | Hospitals, University | 1 | 2003 | 177 | 0.050 |
Why?
| | Ossification, Heterotopic | 1 | 2002 | 17 | 0.050 |
Why?
| | Inpatients | 1 | 2006 | 456 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 72 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 170 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2002 | 126 | 0.050 |
Why?
| | Exons | 1 | 2002 | 330 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2002 | 191 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 985 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1173 | 0.040 |
Why?
| | Prevalence | 1 | 2007 | 2540 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 210 | 0.040 |
Why?
| | Calcinosis | 1 | 2002 | 255 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5032 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4917 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2157 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2047 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1304 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2842 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1923 | 0.040 |
Why?
| | Risk Assessment | 1 | 2006 | 3286 | 0.030 |
Why?
| | Patient Discharge | 1 | 2003 | 858 | 0.030 |
Why?
| | Adult | 4 | 2025 | 35361 | 0.030 |
Why?
| | Lung Diseases | 1 | 2002 | 755 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2002 | 1170 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7060 | 0.030 |
Why?
| | Algorithms | 1 | 2002 | 1626 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 596 | 0.020 |
Why?
| | Resistin | 1 | 2009 | 10 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 37 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2767 | 0.020 |
Why?
| | Medical Audit | 1 | 2008 | 78 | 0.020 |
Why?
| | Leptin | 1 | 2009 | 217 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 159 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 217 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 232 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 2244 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2015 | 1163 | 0.020 |
Why?
| | Program Evaluation | 1 | 2008 | 868 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1204 | 0.010 |
Why?
| | Review Literature as Topic | 1 | 2002 | 66 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10239 | 0.010 |
Why?
| | Lung | 1 | 2009 | 3925 | 0.010 |
Why?
|
|
McDermott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|